AMENO-2: Phase IV Study, National, Multiple Center, Comparative, Randomized, Double Blind, Controlled With Parallel Groups to Determinate the Safety, Tolerability and Efficacy of Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors.

Trial Profile

AMENO-2: Phase IV Study, National, Multiple Center, Comparative, Randomized, Double Blind, Controlled With Parallel Groups to Determinate the Safety, Tolerability and Efficacy of Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors.

Completed
Phase of Trial: Phase IV

Latest Information Update: 23 Jul 2014

At a glance

  • Drugs Aprepitant; Granisetron; Palonosetron
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Acronyms AMENO-2
  • Most Recent Events

    • 12 Jun 2011 Results presented at the 16th Congress of the European Hematology Association.
    • 08 Jun 2011 Results were presented at the Annual Meeting of the European Haematological Association (EHA-2011).
    • 22 Sep 2009 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top